Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the antimicrobial efficacy of the 3M CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.


Clinical Trial Description

The primary efficacy is evaluated by demonstration that the product provides a lower bound of the 95% confidence interval of percent responders that is greater than or equal to 70%. On the abdominal sites, a responder is defined as a subject with a 2-log10 per cm2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at 6 hours. On the inguinal sites, a responder is defined as a subject with a 3-log10 per cm2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at 6 hours. ;


Study Design


Related Conditions & MeSH terms

  • Skin Flora Bacterial Reduction Post-product Application

NCT number NCT01968356
Study type Interventional
Source 3M
Contact
Status Terminated
Phase Phase 3
Start date October 2013
Completion date January 2014